- Home
- PEPG vs EDAP Comparison
PEPG vs EDAP Comparison
Compare PEPG & EDAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEPG
- EDAP
- Stock Information
- Founded
- PEPG 2018
- EDAP 1979
- Country
- PEPG United States
- EDAP France
- Employees
- PEPG N/A
- EDAP N/A
- Industry
- PEPG Biotechnology: Pharmaceutical Preparations
- EDAP Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- PEPG Health Care
- EDAP Health Care
- Exchange
- PEPG Nasdaq
- EDAP Nasdaq
- Market Cap
- PEPG 52.4M
- EDAP 53.8M
- IPO Year
- PEPG 2022
- EDAP 1997
- Fundamental
- Price
- PEPG $1.42
- EDAP $1.81
- Analyst Decision
- PEPG Buy
- EDAP Buy
- Analyst Count
- PEPG 3
- EDAP 3
- Target Price
- PEPG $7.67
- EDAP $8.50
- AVG Volume (30 Days)
- PEPG 216.6K
- EDAP 54.3K
- Earning Date
- PEPG 05-08-2025
- EDAP 05-15-2025
- Dividend Yield
- PEPG N/A
- EDAP N/A
- EPS Growth
- PEPG N/A
- EDAP N/A
- EPS
- PEPG N/A
- EDAP N/A
- Revenue
- PEPG N/A
- EDAP $67,840,467.00
- Revenue This Year
- PEPG N/A
- EDAP N/A
- Revenue Next Year
- PEPG N/A
- EDAP N/A
- P/E Ratio
- PEPG N/A
- EDAP N/A
- Revenue Growth
- PEPG N/A
- EDAP 3.69
- 52 Week Low
- PEPG $0.88
- EDAP $1.26
- 52 Week High
- PEPG $19.30
- EDAP $5.46
- Technical
- Relative Strength Index (RSI)
- PEPG 46.62
- EDAP 45.48
- Support Level
- PEPG $1.35
- EDAP $1.75
- Resistance Level
- PEPG $1.55
- EDAP $1.89
- Average True Range (ATR)
- PEPG 0.15
- EDAP 0.13
- MACD
- PEPG -0.00
- EDAP -0.01
- Stochastic Oscillator
- PEPG 18.42
- EDAP 64.71
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
About EDAP EDAP TMS S.A.
Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.